Gujarat Terce Laboratories Limited (BOM:524314)
36.36
-3.39 (-8.53%)
At close: Aug 18, 2026
BOM:524314 Revenue
Gujarat Terce Laboratories had revenue of 90.02M INR in the quarter ending June 30, 2026, a decrease of -26.95%. This brings the company's revenue in the last twelve months to 456.22M, down -9.11% year-over-year. In the fiscal year ending March 31, 2026, Gujarat Terce Laboratories had annual revenue of 474.73M, down -5.42%.
Revenue (ttm)
456.22M
Revenue Growth
-9.11%
P/S Ratio
0.68
Revenue / Employee
1.95M
Employees
234
Market Cap
309.70M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 474.73M | -27.23M | -5.42% |
| Mar 31, 2025 | 501.95M | 22.21M | 4.63% |
| Mar 31, 2024 | 479.75M | 11.92M | 2.55% |
| Mar 31, 2023 | 467.83M | 66.49M | 16.57% |
| Mar 31, 2022 | 401.34M | 149.56M | 59.40% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Murae Organisor | 8.59B |
| Welcure Drugs and Pharmaceuticals | 3.66B |
| JFL Life Sciences | 1.31B |
| ANG Lifesciences India | 862.13M |
| Deccan Health Care | 818.53M |
| Walpar Nutritions | 757.46M |
| Sandu Pharmaceuticals | 696.24M |
| Panjon | 493.13M |